Lacosamide Tablet, Film Coated
Product Images NDC 70518-4562

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 70518-4562). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm1 (Lacosamide 100mg 70518 4562 00)

Lacosamide 100 mg film-coated tablets, C-V schedule, packaged in a box of 30 tablets. Label indicates oral route and is repackaged by RemedyRepack Inc. The label includes storage instructions and a caution about federal law prohibiting transfer of the drug to others. Manufacturer NDC and general warnings are present.*

FDA Label Image

Remedy_label (Remedy Label)

Lacosamide 100 mg oral tablet packaging label from RemedyRepack Inc. The label shows quantity as 1 tablet, a National Drug Code (NDC) 70518-4562-01, and storage instructions. The label includes cautionary text about federal law and repackaging, along with manufacturer information for Westminster Pharma, Nashville, TN.*

FDA Label Image

Chemical Structure (Lacosamide 01)

Chemical structure of Lacosamide, showing its molecular framework with carbon, nitrogen, oxygen atoms, and a benzene ring as part of its composition.*

FDA Label Image

Figure 1 (Lacosamide 02)

A bar chart showing median percent seizure reduction from baseline in three clinical studies (Study 2, Study 3, Study 4). It compares placebo groups to varying daily doses of Lacosamide, illustrating higher seizure reduction percentages with Lacosamide across studies, with statistically significant differences marked by asterisks.*

FDA Label Image

Figure 2 (Lacosamide 03)

A line graph titled "Proportion of Patients by Responder Rate for Lacosamide and Placebo Groups in Studies 2, 3, and 4." The vertical axis represents responder rate ranging from -100% (worsening) to 100% (improvement). The horizontal axis represents percent of patients from 0 to 100%. The graph shows four lines: solid for Placebo (N=359), dashed for Lacosamide 200 mg/day (N=267), dotted for Lacosamide 400 mg/day (N=466), and dash-dot for Lacosamide 600 mg/day (N=202). The lines illustrate responder rate distributions across patient percentages for each treatment group.*

FDA Label Image

Figure 3 (Lacosamide 04)

A Kaplan-Meier survival curve comparing the proportion of patients over time (days) between Lacosamide and placebo groups. The graph includes number at risk below the time axis and statistical data showing a significant difference with a p-value of 0.001 and a hazard ratio indicating a 45.2% risk reduction for Lacosamide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.